Teva Pharma (TEVA) Reports In-Line Q1 EPS, Reaffirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Teva Pharma (TEVA) PT Lowered to $43 at Deutsche Bank
May 12, 2017 6:31 AM EDTDeutsche Bank lowered its price target on Teva Pharma (NYSE: TEVA) to $43.00 (from $45.00) while maintaining a Buy rating.
Analyst Gregg Gilbert noted TEVA reported decent 1Q results, with EPS upside driven by synergies and cost reductions that more than offset pressures... More
